A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids
about
The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate careAssessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study.Pharmacokinetics of transdermal buprenorphine patch in the elderly.Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.The opioid epidemic and the long-term opioid therapy for chronic noncancer pain revisited: a transatlantic perspective.Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline.Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.Re-enforcing therapeutic effect by positive expectations of pain-relief from our interventions.Long-term treatment in chronic noncancer pain: Results of an observational study comparing opioid and nonopioid therapy.Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality.Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs.Predicting medication persistence to buprenorphine transdermal system.Measuring outcomes of pain management.Fifty years on the Visual Analogue Scale (VAS) for pain-intensity is still good for acute pain. But multidimensional assessment is needed for chronic pain.[Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration].Persistent post-surgical pain (PPP) reduced by high-quality management of acute pain extended to sub-acute pain at homeBuprenorphine – The ideal drug for most clinical indications for an opioid?Statistical pearls: Importance of effect-size, blinding, randomization, publication bias, and the overestimated p-valuesKeeping an open mind: Achieving balance between too liberal and too restrictive prescription of opioids for chronic non-cancer pain: Using a two-edged swordAvoiding the Scylla of NSAIDs and the Charybdis of High-Dose Opioids
P2860
Q35074737-FF262747-024C-469A-9D79-55F96FDA9B4FQ36484526-B003F6DA-D68D-4609-9D46-93B8A1E14914Q36542638-7DA22A98-731A-424B-9A41-0DD3E34D329AQ37964708-D207A464-6A89-4439-9B92-9EBD489B8A0EQ37988549-E320CD9C-3C3E-451C-A207-6DDE1CBF960CQ38778932-593EE978-61E1-4E4C-A6C6-F106F2933F01Q39051851-7B23267D-F26D-49C5-A27F-44CB285B3BDCQ39123423-CDF3A240-B98C-401E-9D26-58F54632FECBQ39150704-DA91B824-7039-4BBC-A41A-DF49A5E6AC61Q39150731-223F6A1A-46C8-4839-AB5E-A92E2A3E3B63Q43076011-8B67C44A-BB08-46E9-8148-83C7CBBA898DQ44116782-22DDE0F4-1775-4044-845B-925E685B54CCQ45163862-12896C30-C529-4521-84D5-26113CCABC41Q50283501-F78D013A-9593-4DEF-8E20-4295DA0B8584Q50283760-66AEAA1C-A902-4699-B38E-62EDF519B994Q53686451-A353AE7D-2578-48B2-B0B8-E0F2803293C8Q57877962-04620937-E387-4316-8253-FA5520913BFBQ57878044-324760DB-D766-4B18-9AFA-C414BE21B70EQ57878250-7346E859-2993-43A3-BE80-96DA450D7328Q57878459-7E2AB113-9E67-4EE7-A454-FF61523192F2Q57878613-FA2728AE-1F63-4B69-A1F7-5333FF810423
P2860
A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2010
@uk
name
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@en
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@nl
type
label
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@en
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@nl
prefLabel
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@en
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@nl
P2093
P2860
P921
P1476
A 6-months, randomised, placeb ...... tients naïve to potent opioids
@en
P2093
Dorthe Tvinnemose
Jan Persson
John Villumsen
Kristian Stengaard-Pedersen
Tone Marte Ljosaa
P2860
P304
P356
10.1016/J.SJPAIN.2010.05.035
P577
2010-07-01T00:00:00Z